Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
Theranexus

BRIEF

published on 07/03/2024 at 07:35, 4 months 18 days ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 4 months 18 days ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 5 months 15 days ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 5 months 15 days ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 6 months 19 days ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF

published on 04/29/2024 at 18:25, 6 months 21 days ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
PRESS RELEASE

published on 04/29/2024 at 18:20, 6 months 21 days ago

THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials

Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF

published on 04/29/2024 at 18:05, 6 months 21 days ago

Theranexus announces its 2023 annual results and the progress of its projects

Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
BRIEF

published on 04/26/2024 at 18:05, 6 months 24 days ago

Theranexus releases voting rights and capital information for March 2024

Share Capital Voting Rights Biopharmaceutical Neurology Theranexus
BRIEF

published on 04/23/2024 at 07:35, 6 months 28 days ago

Theranexus, Diverchim and INSERM obtain funding of 4.7 million euros for the development of a new antisense oligonucleotide

Biothérapies France 2030 Funding Antisense Oligonucleotide Rare Neurological Diseases Autophagy

Accesswire

Published on 11/21/2024 at 13:30, 25 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 25 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 55 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 55 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 55 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 40 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 20 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 40 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 48 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 55 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 57 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 35 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 10 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 10 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE